Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

Florida State University researchers are working on new approaches to deciphering genetic data that may lead to new, more targeted prostate cancer treatments. Prostate cancer, which affects one in ...

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...

Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...